Rigor Reviewed

Rigor-Reviewed Manuscript

Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.

Name: Αlpha¹ Rigor Record — Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.
Item: Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.
Rating: 96
Author: Αlpha¹

Auchus RJ, Hamidi O, Pivonello R, Bancos I, Russo G, Witchel SF, Isidori AM, Rodien P, Srirangalingam U, Kiefer FW, Falhammar H, Merke DP, Reisch N, Sarafoglou K, Cutler GB Jr, Sturgeon J, Roberts E, Lin VH, Chan JL, Farber RH, CAHtalyst Adult Trial Investigators

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 2 high issues for “Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 9 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 3 randomized controlled trial with rigorous design, clear reporting of methods, and appropriate statistical analysis. The main weaknesses are the lack of a clear data availability statement and the failure to name the statistical software, both minor reporting gaps. A minor internal inconsistency in participant counts and retrospective registration of one phase 2 trial are noted but do not undermine the main findings.

Both reviewers agreed on study type (interventional) and on all dimension statuses. The statistics verification covered only 2 tests (those with test statistics/df or effect+CI); other p-values were not machine-verified. The integrity check flagged a minor internal contradiction in participant counts and retrospective registration of NCT03525886, which are noted but do not affect dimension statuses.

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior research on CAH pathophysiology, the limitations of current glucocorticoid therapy, and phase 2 proof-of-concept studies of crinecerfont. The rationale linking CRF1 antagonism to reduced ACTH and adrenal androgens is clearly articulated. The study objectives follow logically from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a clear scientific premise with adequate citation of prior work and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraph 3]

“Crinecerfont is a novel orally administered CRF 1 antagonist that reduced key hormone biomarkers in phase 2 studies in adults ( NCT03525886 ) and adolescents ( NCT04045145 ) with CAH.”

direct quote[Introduction, paragraph 2]

“One promising new strategy for reducing adrenal androgen overproduction through a GC-independent mechanism is CRF type 1 receptor (CRF 1 ) antagonism to reduce ACTH secretion, thus potentially allowing for physiological GC dosing.”